Facts and Fictions About [18F]FDG versus Other Tracers in Managing Patients with Brain Tumors

Withofs, Nadia; Kumar, Rakesh; Alavi, Abass; Hustinx, Roland

doi:10.1016/j.cpet.2022.03.004

Cited by 5 publications

(2 citation statements)

References 118 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[ 18 F]FDG PET of the brain thus enables whole brain glucose metabolism to be mapped, showing different pathological conditions such as epilepsy [21], brain tumors (highgrade gliomas) [22], and NDs [23]. The reduction of [ 18 F]FDG uptake in selected brain regions can also help clinicians to recognize NDs, which also helps to improve the differential diagnosis.…”

Section: [ 18 F]fdg Petmentioning

confidence: 99%

Positron Emission Tomography Molecular Imaging of the Major Neurodegenerative Disorders: Overview and Pictorial Essay, from a Nuclear Medicine Center's Perspective

Calabria,

Leporace,

Cimini

et al. 2023

J. Integr. Neurosci.

View full text Add to dashboard Cite

Computed tomography (CT) and magnetic resonance imaging (MRI) provide key structural information on brain pathophysiology. Positron emission tomography (PET) measures metabolism in the living brain; it plays an important role in molecular neuroimaging and is rapidly expanding its field of application to the study of neurodegenerative diseases. Different PET radiopharmaceuticals allow in vivo characterization and quantization of biological processes at the molecular and cellular levels, from which many neurodegenerative diseases develop. In addition, hybrid imaging tools such as PET/CT and PET/MRI support the utility of PET, enabling the anatomical mapping of functional data. In this overview, we describe the most commonly used PET tracers in the diagnostic work-up of patients with Alzheimer's disease, Parkinson's disease, and other neurodegenerative diseases. We also briefly discuss the pathophysiological processes of tracer uptake in the brain, detailing their specific cellular pathways in clinical cases. This overview is limited to imaging agents already applied in human subjects, with particular emphasis on those tracers used in our department.

show abstract

Section: [ 18 F]fdg Petmentioning

confidence: 99%

Positron Emission Tomography Molecular Imaging of the Major Neurodegenerative Disorders: Overview and Pictorial Essay, from a Nuclear Medicine Center's Perspective

Calabria,

Leporace,

Cimini

et al. 2023

J. Integr. Neurosci.

View full text Add to dashboard Cite

show abstract

“…Since energy metabolism generally increases with increasing malignancy grade, 18 F-FDG has often been used to differentiate between WHO grades, and recently even between IDH-mutated and IDH-wildtype tumors (44). It can also help differentiate tumor recurrence from treatment-related changes, and recent radiomics techniques with also show promise in predicting Ki-67 expression and patient prognosis non-invasively (45,46). The main limitation of 18 F-FDG lies in the generically high rate of glucose metabolism in the healthy cerebral cortex, leading to low tumor-to-normal-tissue (T/N) ratios for most tumors except those with very high cellular density and metabolic rate, like lymphoma (47).…”

Section: Glucose-based Agentsmentioning

confidence: 99%

PET Agents for Primary Brain Tumor Imaging

van der Kolk,

Henssen,

Schroeder

et al. 2023

PET Agents for Primary Brain Tumor Imaging

View full text Add to dashboard Cite

The role of molecular imaging with positron emission tomography (PET) for diagnosis, treatment planning and post-treatment monitoring of brain tumors has grown substantially in the last decades. In the last 25 years, almost 50 different PET agents have been developed and tested in human clinical studies. While some of these PET agents are yet to make their way into clinical practice, others have already established pivotal roles in brain tumor imaging. Although all these agents share an affinity for brain tumor cells, they target different tumor-altered molecular pathways within these cells: some agents are taken up by the cell through overexpressed transporters and become trapped, altered, or incorporated into upregulated metabolic pathways, while other agents bind to overexpressed receptors or to cells Note to the Reader: This open access monograph (ISBN: 978-0-6458663-0-8) has been peer

show abstract